ReviewScience (New York, N.Y.)2013
Neutralizing tumor-promoting chronic inflammation: a magic bullet?
Review in Science (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 630 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients
A Phase 1b/2 Study of Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Who cites it
630 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Necroptosis in pancreatic cancer: Molecular mechanisms and therapeutic implications.Apoptosis : an international journal on programmed cell death · 2026Pooled it
- Research landscape and frontiers of non-alcoholic steatohepatitis-associated hepatocellular carcinoma: a bibliometric and visual analysis.Frontiers in pharmacology · 2023Pooled it
- Proteomic signatures identify significantly different inflammatory breast tissue microenvironments depending on mammographic density or estrogen exposure.NPJ breast cancer · 2026Article
- Targeting cysteinyl leukotriene receptor 1 reprograms tumor-promoting myelopoiesis and overcomes immune checkpoint therapy resistance.Nature cancer · 2026Article
- Identification of macrophage-enriched genes in ovarian cancer by single-cell RNA sequencing and establishment of a prognosis model.Scientific reports · 2026Article
- Understanding the mechanisms underlying obesity induced tumorigenesis: therapeutic perspectives to manage dysregulated lipid metabolism.Discover oncology · 2026Review
- Chronic Stress, Immune Suppression, and Cancer Occurrence: Unveiling the Connection Using Survey Data and Predictive Models.Medical sciences (Basel, Switzerland) · 2026Article
- Dexamethasone promotes neutrophil ROS-mediated tumor killing through the glucocorticoid receptor.Oncogene · 2026Article
- Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- 3D pentaculture model unveils malignant cell-driven macrophage polarization in high-grade serous ovarian cancer.Nature communications · 2026Article
- An ultrasmall core-shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironments.Nature nanotechnology · 2026Article
- Correlation between immune suppressor cells and cytokines in the peripheral blood of patients with chronic lymphocytic leukemia.Frontiers in oncology · 2026Article
- Downregulation of TNFAIP3 Associated With Poor Prognosis and Immune Response in Breast Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- Article
- Clinical characteristics of colorectal polyps in patients with non-alcoholic fatty liver disease in high altitude areas.World journal of gastrointestinal oncology · 2025Article
- Eosinophils and Bioactive Lipid Mediators Regulate Skin Inflammation and Cancer Growth.The Journal of investigative dermatology · 2025Article
- Ageing, immune fitness and cancer.Nature reviews. Cancer · 2025Review
- ZC3H12A: A Critical Mediator of Inflammation, Tumor Immunotherapy, and Metabolic-Immune Crosstalk-Implications for Disease Treatment.Biomolecules · 2025Review
- The Role of Immunotherapy and Radiation Therapy in the Treatment of Breast Cancer.Biomedicines · 2025Review
- Association of HPV in the Genesis of Head and Neck Squamous Cell Carcinoma: A Case-Control Study in a Bulgarian Cohort.Cancers · 2025Article
570 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
There have been substantial advances in cancer diagnostics and therapies in the past decade. Besides chemotherapeutic agents and radiation therapy, approaches now include targeting cancer cell-intrinsic mediators linked to genetic aberrations in cancer cells, in addition to cancer cell-extrinsic pathways, especially those regulating vascular programming of solid tumors. More recently, immunotherapeutics have entered the clinic largely on the basis of the recognition that several immune cell subsets, when chronically activated, foster tumor development. Here, we discuss clinical and experimental studies delineating protumorigenic roles for immune cell subsets that are players in cancer-associated inflammation. Some of these cells can be targeted to reprogram their function, leading to resolution, or at least neutralization, of cancer-promoting chronic inflammation, thereby facilitating cancer rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.